IBD Clinical Trials | BMS Study Connect

Helping Your Patients Understand Inflammatory Bowel Disease (IBD) and How a Study Drug May Work

The purpose of this study is to determine the safety and efficacy of the study drug deucravacitinib (also known as BMS-986165) compared to placebo.

This video will help participants considering to join the BMS IBD clinical study learn more about IBD and how the study medication BMS-986165 is thought to affect the gut.

1:28

divider

Now Enrolling: Clinical Trials for IBD

Click the links below to review complete eligibility criteria, study site locations, and contact information for these studies.

RPC01-3201

Recruiting

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

RPC01-3202

Recruiting

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

View Trial Details

IM047-023

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

View Trial Details

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -

Call 855-907-3286 or email clinical.trials@bms.com

Helping Your Patients Understand Inflammatory Bowel Disease (IBD) and How a Study Drug May Work

Now Enrolling: Clinical Trials for IBD

About

About

NEED HELP?

NEED HELP?